Article List
List all articles in the database by earliest discovery_date
GET /articles/?format=api&page=6
{ "count": 24931, "next": "http://api.gregory-ms.com/articles/?format=api&page=7", "previous": "http://api.gregory-ms.com/articles/?format=api&page=5", "results": [ { "article_id": 283879, "title": "Regulatory mechanisms of PD-1/PD-L1 in cancers", "summary": "<jats:title>Abstract</jats:title><jats:p>Immune evasion contributes to cancer growth and progression. Cancer cells have the ability to activate different immune checkpoint pathways that harbor immunosuppressive functions. The programmed death protein 1 (PD-1) and programmed cell death ligands (PD-Ls) are considered to be the major immune checkpoint molecules. The interaction of PD-1 and PD-L1 negatively regulates adaptive immune response mainly by inhibiting the activity of effector T cells while enhancing the function of immunosuppressive regulatory T cells (Tregs), largely contributing to the maintenance of immune homeostasis that prevents dysregulated immunity and harmful immune responses. However, cancer cells exploit the PD-1/PD-L1 axis to cause immune escape in cancer development and progression. Blockade of PD-1/PD-L1 by neutralizing antibodies restores T cells activity and enhances anti-tumor immunity, achieving remarkable success in cancer therapy. Therefore, the regulatory mechanisms of PD-1/PD-L1 in cancers have attracted an increasing attention. This article aims to provide a comprehensive review of the roles of the PD-1/PD-L1 signaling in human autoimmune diseases and cancers. We summarize all aspects of regulatory mechanisms underlying the expression and activity of PD-1 and PD-L1 in cancers, including genetic, epigenetic, post-transcriptional and post-translational regulatory mechanisms. In addition, we further summarize the progress in clinical research on the antitumor effects of targeting PD-1/PD-L1 antibodies alone and in combination with other therapeutic approaches, providing new strategies for finding new tumor markers and developing combined therapeutic approaches.</jats:p>", "link": "https://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-024-02023-w", "published_date": "2024-05-17T23:00:00Z", "sources": [ "BioMedCentral" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Springer Science and Business Media LLC", "container_title": "Molecular Cancer", "authors": [ { "author_id": 235471, "given_name": "Xin", "family_name": "Lin", "ORCID": "http://orcid.org/0000-0002-1563-8168", "country": null }, { "author_id": 351464, "given_name": "Kuan", "family_name": "Kang", "ORCID": null, "country": null }, { "author_id": 241689, "given_name": "Pan", "family_name": "Chen", "ORCID": null, "country": null }, { "author_id": 351465, "given_name": "Zhaoyang", "family_name": "Zeng", "ORCID": null, "country": null }, { "author_id": 351466, "given_name": "Guiyuan", "family_name": "Li", "ORCID": null, "country": null }, { "author_id": 344935, "given_name": "Wei", "family_name": "Xiong", "ORCID": null, "country": null }, { "author_id": 351467, "given_name": "Mei", "family_name": "Yi", "ORCID": null, "country": null }, { "author_id": 351468, "given_name": "Bo", "family_name": "Xiang", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2024-05-18T12:04:00.964488Z", "noun_phrases": null, "doi": "10.1186/s12943-024-02023-w", "access": "restricted", "takeaways": "Cancer cells exploit the PD-1/PD-L1 axis to cause immune escape in cancer development and progression. Blockade of the axis by neutralizing antibodies restores T cells activity and enhances anti-tumor immunity.", "categories": [] }, { "article_id": 283878, "title": "Blood biomarkers of neurodegeneration associate differently with amyloid deposition, medial temporal atrophy, and cerebrovascular changes in APOE ε4-enriched cognitively unimpaired elderly", "summary": "<jats:title>Abstract</jats:title><jats:sec>\n <jats:title>Background</jats:title>\n <jats:p>Alzheimer’s disease (AD) is characterized by the accumulation of amyloid-β (Aβ) plaques, neurofibrillary tau tangles, and neurodegeneration in the brain parenchyma. Here, we aimed to (i) assess differences in blood and imaging biomarkers used to evaluate neurodegeneration among cognitively unimpaired <jats:italic>APOE</jats:italic> ε4 homozygotes, heterozygotes, and non-carriers with varying risk for sporadic AD, and (ii) to determine how different cerebral pathologies (i.e., Aβ deposition, medial temporal atrophy, and cerebrovascular pathology) contribute to blood biomarker concentrations in this sample.</jats:p>\n </jats:sec><jats:sec>\n <jats:title>Methods</jats:title>\n <jats:p>Sixty <jats:italic>APOE</jats:italic> ε4 homozygotes (<jats:italic>n</jats:italic> = 19), heterozygotes (<jats:italic>n</jats:italic> = 21), and non-carriers (<jats:italic>n</jats:italic> = 20) ranging from 60 to 75 years, were recruited in collaboration with Auria biobank (Turku, Finland). Participants underwent Aβ-PET ([<jats:sup>11</jats:sup>C]PiB), structural brain MRI including T1-weighted and T2-FLAIR sequences, and blood sampling for measuring serum neurofilament light chain (NfL), plasma total tau (t-tau), plasma N-terminal tau fragments (NTA-tau) and plasma glial fibrillary acidic protein (GFAP). [<jats:sup>11</jats:sup>C]PiB standardized uptake value ratio was calculated for regions typical for Aβ accumulation in AD. MRI images were analysed for regional volumes, atrophy scores, and volumes of white matter hyperintensities. Differences in biomarker levels and associations between blood and imaging biomarkers were tested using uni- and multivariable linear models (unadjusted and adjusted for age and sex).</jats:p>\n </jats:sec><jats:sec>\n <jats:title>Results</jats:title>\n <jats:p>Serum NfL concentration was increased in <jats:italic>APOE</jats:italic> ε4 homozygotes compared with non-carriers (mean 21.4 pg/ml (SD 9.5) vs. 15.5 pg/ml (3.8), <jats:italic>p</jats:italic> = 0.013), whereas other blood biomarkers did not differ between the groups (<jats:italic>p</jats:italic> > 0.077 for all). From imaging biomarkers, hippocampal volume was significantly decreased in <jats:italic>APOE</jats:italic> ε4 homozygotes compared with non-carriers (6.71 ml (0.86) vs. 7.2 ml (0.7), <jats:italic>p</jats:italic> = 0.029). In the whole sample, blood biomarker levels were differently predicted by the three measured cerebral pathologies; serum NfL concentration was associated with cerebrovascular pathology and medial temporal atrophy, while plasma NTA-tau associated with medial temporal atrophy. Plasma GFAP showed significant association with both medial temporal atrophy and Aβ pathology. Plasma t-tau concentration did not associate with any of the measured pathologies.</jats:p>\n </jats:sec><jats:sec>\n <jats:title>Conclusions</jats:title>\n <jats:p>Only increased serum NfL concentrations and decreased hippocampal volume was observed in cognitively unimpaired APOEε4 homozygotes compared to non-carriers. In the whole population the concentrations of blood biomarkers were affected in distinct ways by different pathologies.</jats:p>\n </jats:sec>", "link": "https://alzres.biomedcentral.com/articles/10.1186/s13195-024-01477-w", "published_date": "2024-05-17T23:00:00Z", "sources": [ "BioMedCentral" ], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Springer Science and Business Media LLC", "container_title": "Alzheimer's Research & Therapy", "authors": [ { "author_id": 315632, "given_name": "Mikko", "family_name": "Koivumäki", "ORCID": null, "country": null }, { "author_id": 351463, "given_name": "Laura", "family_name": "Ekblad", "ORCID": null, "country": null }, { "author_id": 315633, "given_name": "Juan", "family_name": "Lantero-Rodriguez", "ORCID": null, "country": null }, { "author_id": 307773, "given_name": "Nicholas J.", "family_name": "Ashton", "ORCID": null, "country": null }, { "author_id": 315634, "given_name": "Semi", "family_name": "Helin", "ORCID": null, "country": null }, { "author_id": 251095, "given_name": "Riitta", "family_name": "Parkkola", "ORCID": null, "country": null }, { "author_id": 298134, "given_name": "Jyrki", "family_name": "Lötjönen", "ORCID": null, "country": null }, { "author_id": 315639, "given_name": "Juha O.", "family_name": "Rinne", "ORCID": null, "country": null }, { "author_id": 315630, "given_name": "Anniina", "family_name": "Snellman", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2024-05-18T12:03:50.885519Z", "noun_phrases": null, "doi": "10.1186/s13195-024-01477-w", "access": "restricted", "takeaways": null, "categories": [] }, { "article_id": 283877, "title": "Lysosomal and synaptic dysfunction markers in longitudinal cerebrospinal fluid of de novo Parkinson’s disease", "summary": "<jats:title>Abstract</jats:title><jats:p>Lysosomal and synaptic dysfunctions are hallmarks in neurodegeneration and potentially relevant as biomarkers, but data on early Parkinson’s disease (PD) is lacking. We performed targeted mass spectrometry with an established protein panel, assessing autophagy and synaptic function in cerebrospinal fluid (CSF) of drug-naïve de novo PD, and sex-/age-matched healthy controls (HC) cross-sectionally (88 PD, 46 HC) and longitudinally (104 PD, 58 HC) over 10 years. Multiple markers of autophagy, synaptic plasticity, and secretory pathways were reduced in PD. We added samples from prodromal subjects (9 cross-sectional, 12 longitudinal) with isolated REM sleep behavior disorder, revealing secretogranin-2 already decreased compared to controls. Machine learning identified neuronal pentraxin receptor and neurosecretory protein VGF as most relevant for discriminating between groups. CSF levels of LAMP2, neuronal pentraxins, and syntaxins in PD correlated with clinical progression, showing predictive potential for motor- and non-motor symptoms as a valid basis for future drug trials.</jats:p>", "link": "https://pubmed.ncbi.nlm.nih.gov/38760408/?fc=20210216052009&ff=20240518232531&v=2.18.0.post9+e462414", "published_date": "2024-05-17T10:00:00Z", "sources": [], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Springer Science and Business Media LLC", "container_title": "npj Parkinson's Disease", "authors": [ { "author_id": 351409, "given_name": "Michael", "family_name": "Bartl", "ORCID": "http://orcid.org/0000-0002-7752-2443", "country": "DE" }, { "author_id": 301179, "given_name": "Johanna", "family_name": "Nilsson", "ORCID": null, "country": null }, { "author_id": 351410, "given_name": "Mohammed", "family_name": "Dakna", "ORCID": null, "country": null }, { "author_id": 351411, "given_name": "Sandrina", "family_name": "Weber", "ORCID": "http://orcid.org/0000-0001-5713-2141", "country": null }, { "author_id": 218130, "given_name": "Sebastian", "family_name": "Schade", "ORCID": "http://orcid.org/0000-0002-6316-6804", "country": null }, { "author_id": 351412, "given_name": "Mary", "family_name": "Xylaki", "ORCID": "http://orcid.org/0000-0002-7892-8621", "country": null }, { "author_id": 351413, "given_name": "Bárbara", "family_name": "Fernandes Gomes", "ORCID": null, "country": null }, { "author_id": 351414, "given_name": "Marielle", "family_name": "Ernst", "ORCID": null, "country": null }, { "author_id": 268328, "given_name": "Maria-Lucia", "family_name": "Muntean", "ORCID": null, "country": null }, { "author_id": 268334, "given_name": "Friederike", "family_name": "Sixel-Döring", "ORCID": null, "country": null }, { "author_id": 267275, "given_name": "Claudia", "family_name": "Trenkwalder", "ORCID": null, "country": null }, { "author_id": 150775, "given_name": "Henrik", "family_name": "Zetterberg", "ORCID": "http://orcid.org/0000-0003-3930-4354", "country": null }, { "author_id": 291837, "given_name": "Ann", "family_name": "Brinkmalm", "ORCID": null, "country": null }, { "author_id": 207993, "given_name": "Brit", "family_name": "Mollenhauer", "ORCID": "http://orcid.org/0000-0001-8437-3645", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2024-05-18T10:25:51.507504Z", "noun_phrases": null, "doi": "10.1038/s41531-024-00714-1", "access": "open", "takeaways": "Data on early Parkinson's disease (PD) is lacking. Multiple markers of autophagy, synaptic plasticity, and secretory pathways were reduced in PD. CSF levels of LAMP2, neuronal pentraxins and syntaxins in PD correlated with clinical progression.", "categories": [] }, { "article_id": 283876, "title": "Making Information About Cladribine Tablets Accessible to People with Multiple Sclerosis: A Patient-Survey-Led Narrative Review for Healthcare Professionals", "summary": "Cladribine tablets have been granted marketing authorization in Europe and approved by the Food and Drug Administration (FDA) in the USA to treat relapsing forms of multiple sclerosis (MS). However, people with MS (PwMS) may be more familiar, and therefore more confident, with treatments requiring long-term and frequent dosing. Differences in such treatment strategies can lead to questions relating to how short-course non-continuous treatments, such as cladribine tablets, can work and how well...", "link": "https://pubmed.ncbi.nlm.nih.gov/38760637/?fc=20210216052009&ff=20240519052532&v=2.18.0.post9+e462414", "published_date": "2024-05-17T10:00:00Z", "sources": [], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Springer Science and Business Media LLC", "container_title": "Neurology and Therapy", "authors": [ { "author_id": 351406, "given_name": "Ardra", "family_name": "Shephard", "ORCID": null, "country": null }, { "author_id": 309437, "given_name": "Laura", "family_name": "Kolaczkowski", "ORCID": null, "country": null }, { "author_id": 322971, "given_name": "Noreen", "family_name": "Barker", "ORCID": null, "country": null }, { "author_id": 351407, "given_name": "Donna", "family_name": "Nahal", "ORCID": null, "country": null }, { "author_id": 150219, "given_name": "Celia", "family_name": "Oreja-Guevara", "ORCID": "http://orcid.org/0000-0002-9221-5716", "country": null }, { "author_id": 259842, "given_name": "Saúl", "family_name": "Reyes", "ORCID": null, "country": null }, { "author_id": 351408, "given_name": "Helen", "family_name": "Gray", "ORCID": null, "country": null }, { "author_id": 282107, "given_name": "Hashem", "family_name": "Salloukh", "ORCID": null, "country": null }, { "author_id": 143429, "given_name": "Gavin", "family_name": "Giovannoni", "ORCID": "http://orcid.org/0000-0001-9995-1700", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2024-05-18T10:25:49.991683Z", "noun_phrases": null, "doi": "10.1007/s40120-024-00608-7", "access": "open", "takeaways": "Cladribine tablets have been granted marketing authorization in Europe and approved by the FDA in the USA to treat relapsing forms of MS. People with MS (", "categories": [] }, { "article_id": 283874, "title": "Antipsychotics use in autoimmune encephalitis and multiple sclerosis: Impact on hospitalization duration", "summary": "No abstract", "link": "https://pubmed.ncbi.nlm.nih.gov/38759353/?fc=20210216052009&ff=20240518192535&v=2.18.0.post9+e462414", "published_date": "2024-05-17T10:00:00Z", "sources": [], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Elsevier BV", "container_title": "Journal of Clinical Neuroscience", "authors": [ { "author_id": 305694, "given_name": "Prateek Kumar", "family_name": "Panda", "ORCID": null, "country": null }, { "author_id": 222089, "given_name": "Indar Kumar", "family_name": "Sharawat", "ORCID": "http://orcid.org/0000-0002-7003-7218", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2024-05-18T08:25:48.591022Z", "noun_phrases": null, "doi": "10.1016/j.jocn.2024.05.008", "access": "restricted", "takeaways": null, "categories": [] }, { "article_id": 283873, "title": "Induction of indoleamine 2,3-dioxygenase 1 expression in neurons of the central nervous system through inhibition of histone deacetylases blocks the progression of experimental autoimmune encephalomyelitis", "summary": "CONCLUSIONS: Overall, our results suggest that IDO1 tryptophan metabolites produced by neuronal cells may act on AHR in pathogenic CD4^(+) T cells in a paracrine fashion in the CNS and that the specific induction of IDO1 expression in neurons at disease-afflicted sites can be considered a therapeutic approach to block the progression of multiple sclerosis without affecting systemic immunity.", "link": "https://pubmed.ncbi.nlm.nih.gov/38759372/?fc=20210216052009&ff=20240518232531&v=2.18.0.post9+e462414", "published_date": "2024-05-17T10:00:00Z", "sources": [], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Elsevier BV", "container_title": "International Immunopharmacology", "authors": [ { "author_id": 351397, "given_name": "Chae Eun", "family_name": "Kim", "ORCID": null, "country": null }, { "author_id": 351398, "given_name": "Soung-Min", "family_name": "Lee", "ORCID": null, "country": null }, { "author_id": 351399, "given_name": "Eun Hye", "family_name": "Yoon", "ORCID": null, "country": null }, { "author_id": 351400, "given_name": "Hae Jeong", "family_name": "Won", "ORCID": null, "country": null }, { "author_id": 351401, "given_name": "Yu Jin", "family_name": "Jung", "ORCID": null, "country": null }, { "author_id": 351402, "given_name": "Yangjin", "family_name": "Jegal", "ORCID": null, "country": null }, { "author_id": 351403, "given_name": "Dong Hyun", "family_name": "Kim", "ORCID": null, "country": null }, { "author_id": 351404, "given_name": "Byungsuk", "family_name": "Kwon", "ORCID": null, "country": null }, { "author_id": 351405, "given_name": "Su-Kil", "family_name": "Seo", "ORCID": "http://orcid.org/0000-0001-9604-4849", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2024-05-18T08:25:47.336885Z", "noun_phrases": null, "doi": "10.1016/j.intimp.2024.112246", "access": "restricted", "takeaways": "IDO1 tryptophan metabolites produced by neuronal cells may act on AHR in pathogenic CD4+ T", "categories": [] }, { "article_id": 283872, "title": "Intact natalizumab pharmacokinetics is impacted by endogenous IgG4 concentration", "summary": "CONCLUSIONS: Intact NAT concentration is influenced by both NAT pharmacokinetics and endogenous IgG4 levels. Patients with low IgG4 levels can have high concentrations of intact NAT even with lower levels of total NAT, which may explain cases of NAT-associated progressive multifocal leukoencephalopathy (PML) in such patients. Monitoring both forms of NAT could better guide dosing, maximizing drug efficacy and safety.", "link": "https://pubmed.ncbi.nlm.nih.gov/38759421/?fc=20210216052009&ff=20240518232531&v=2.18.0.post9+e462414", "published_date": "2024-05-17T10:00:00Z", "sources": [], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Elsevier BV", "container_title": "Multiple Sclerosis and Related Disorders", "authors": [ { "author_id": 351394, "given_name": "Lesley J.", "family_name": "Page", "ORCID": "http://orcid.org/0000-0003-2538-5819", "country": null }, { "author_id": 351395, "given_name": "Iona F.", "family_name": "Pay", "ORCID": null, "country": null }, { "author_id": 297587, "given_name": "Edward T.", "family_name": "Castellana", "ORCID": null, "country": null }, { "author_id": 297586, "given_name": "Raphaela", "family_name": "Heussen", "ORCID": null, "country": null }, { "author_id": 351396, "given_name": "Tamara", "family_name": "Hoyt", "ORCID": null, "country": null }, { "author_id": 246349, "given_name": "John", "family_name": "Foley", "ORCID": null, "country": null }, { "author_id": 297588, "given_name": "Bradley T.", "family_name": "Messmer", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2024-05-18T08:25:46.199150Z", "noun_phrases": null, "doi": "10.1016/j.msard.2024.105667", "access": "restricted", "takeaways": "Intact NAT concentration is influenced by both NAT pharmacokinetics and IgG4 levels. Monitoring both forms of NAT could better guide d", "categories": [ { "category_id": 7, "category_description": "", "category_name": "Natalizumab", "category_slug": "natalizumab", "category_terms": [ "natalizumab", "tysabri" ], "article_count": 305 } ] }, { "article_id": 283871, "title": "Reliability and validity of the 4-meter walk test patients with multiple sclerosis", "summary": "CONCLUSION: The 4-MWT was found to be valid and reliable for PwMS. It is concluded that the 4-MWT is a feasible assessment method for clinical and methodological studies of PwMS with mild to moderate disability.", "link": "https://pubmed.ncbi.nlm.nih.gov/38759422/?fc=20210216052009&ff=20240518232531&v=2.18.0.post9+e462414", "published_date": "2024-05-17T10:00:00Z", "sources": [], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Elsevier BV", "container_title": "Multiple Sclerosis and Related Disorders", "authors": [ { "author_id": 160206, "given_name": "Taskin", "family_name": "Ozkan", "ORCID": "http://orcid.org/0000-0001-9448-0516", "country": "TR" }, { "author_id": 323246, "given_name": "Nezehat Ozgul", "family_name": "Unluer", "ORCID": null, "country": null }, { "author_id": 351392, "given_name": "Yasemin", "family_name": "Ates-Sari", "ORCID": null, "country": null }, { "author_id": 351393, "given_name": "Suleyman Furkan", "family_name": "Hangun", "ORCID": null, "country": null }, { "author_id": 343799, "given_name": "Gonul", "family_name": "Vural", "ORCID": "http://orcid.org/0000-0002-1245-7273", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2024-05-18T08:25:45.077521Z", "noun_phrases": null, "doi": "10.1016/j.msard.2024.105679", "access": "restricted", "takeaways": "", "categories": [] }, { "article_id": 283870, "title": "Neuromyelitis optica spectrum disorders registry system in Iran: Validity of data sets", "summary": "CONCLUSION: The implementing of NMORI is important in a developing country such as Iran with significant increasing prevalence of this disease. This registry facilitates a uniform and valid diagnosis and is considered valid for clinical investigation and epidemiological research on NMOSD. Scientists and healthcare policymakers can rely on a validated data set in order to have access to accurate data.", "link": "https://pubmed.ncbi.nlm.nih.gov/38759423/?fc=20210216052009&ff=20240518232531&v=2.18.0.post9+e462414", "published_date": "2024-05-17T10:00:00Z", "sources": [], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Elsevier BV", "container_title": "Multiple Sclerosis and Related Disorders", "authors": [ { "author_id": 271174, "given_name": "Faezeh", "family_name": "Khodaie", "ORCID": null, "country": null }, { "author_id": 351390, "given_name": "Mahsa", "family_name": "Mohamadi", "ORCID": null, "country": null }, { "author_id": 351391, "given_name": "Yasamin", "family_name": "Ebrahimi", "ORCID": null, "country": null }, { "author_id": 184389, "given_name": "Mohammad Ali", "family_name": "Sahraian", "ORCID": "http://orcid.org/0000-0002-3224-8807", "country": null }, { "author_id": 248363, "given_name": "Abdorreza Naser", "family_name": "Moghadasi", "ORCID": null, "country": null }, { "author_id": 262175, "given_name": "Saeideh", "family_name": "Ayoubi", "ORCID": null, "country": null }, { "author_id": 242680, "given_name": "Houman", "family_name": "Goudarzi", "ORCID": null, "country": null }, { "author_id": 249415, "given_name": "Sepideh", "family_name": "Paybast", "ORCID": null, "country": null }, { "author_id": 303243, "given_name": "Naser", "family_name": "Kamyari", "ORCID": null, "country": null }, { "author_id": 250203, "given_name": "Nasrin", "family_name": "Asgari", "ORCID": null, "country": null }, { "author_id": 241745, "given_name": "Kazuo", "family_name": "Fujihara", "ORCID": null, "country": null }, { "author_id": 237455, "given_name": "Hora", "family_name": "Heidari", "ORCID": null, "country": null }, { "author_id": 206649, "given_name": "Sharareh", "family_name": "Eskandarieh", "ORCID": "http://orcid.org/0000-0002-8942-9983", "country": null }, { "author_id": 351430, "given_name": "Mahsa Mohammadi", "family_name": "Lapevandani", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2024-05-18T08:25:43.730591Z", "noun_phrases": null, "doi": "10.1016/j.msard.2024.105685", "access": "restricted", "takeaways": "The implementing of NMORI is important in a developing country such as Iran. This registry facilitates a uniform and valid diagnosis and is considered", "categories": [] }, { "article_id": 283869, "title": "Investigating the effects of 25-hydroxyvitamin D3 on clinical outcomes in multiple sclerosis patients: A randomized, double-blind clinical trial- a pilot study", "summary": "CONCLUSIONS: The trial shows that calcifediol is more effective in rapidly increasing 25(OH)D(3) levels in MS patients compared to cholecalciferol when administrated at a similar dosage.", "link": "https://pubmed.ncbi.nlm.nih.gov/38759424/?fc=20210216052009&ff=20240518232531&v=2.18.0.post9+e462414", "published_date": "2024-05-17T10:00:00Z", "sources": [], "teams": [ { "id": 1, "name": "Team Gregory" } ], "subjects": [ { "subject_name": "Multiple Sclerosis", "description": null } ], "publisher": "Elsevier BV", "container_title": "Multiple Sclerosis and Related Disorders", "authors": [ { "author_id": 174261, "given_name": "Zhila", "family_name": "Maghbooli", "ORCID": "http://orcid.org/0000-0001-8858-6269", "country": null }, { "author_id": 285780, "given_name": "Arash", "family_name": "Shirvani", "ORCID": null, "country": null }, { "author_id": 248363, "given_name": "Abdorreza Naser", "family_name": "Moghadasi", "ORCID": null, "country": null }, { "author_id": 272932, "given_name": "Tarlan", "family_name": "Varzandi", "ORCID": null, "country": null }, { "author_id": 351389, "given_name": "Sara", "family_name": "Hamtaei Ghashti", "ORCID": null, "country": null }, { "author_id": 184389, "given_name": "Mohammad Ali", "family_name": "Sahraian", "ORCID": "http://orcid.org/0000-0002-3224-8807", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2024-05-18T08:25:42.535979Z", "noun_phrases": null, "doi": "10.1016/j.msard.2024.105673", "access": "restricted", "takeaways": "", "categories": [] } ] }